Property:Outcome specification
This is a property of type Text.
W
Wyatt et al. (2012): Health-Related Quality-of-Life Outcomes: A Reflexology Trial With Patients With Advanced-Stage Breast Cancer +
Dyspnea with a single item from the FACT-B other concerns subscale +
Wyatt et al. (2012): Health-Related Quality-of-Life Outcomes: A Reflexology Trial With Patients With Advanced-Stage Breast Cancer +
Disruption of daily activities due to fatigue with single item from the BFI +
Wyatt et al. (2012): Health-Related Quality-of-Life Outcomes: A Reflexology Trial With Patients With Advanced-Stage Breast Cancer +
NA +
Wyatt et al. (2012): Health-Related Quality-of-Life Outcomes: A Reflexology Trial With Patients With Advanced-Stage Breast Cancer +
Fatigue severity with single item from the BFI +
Wyatt et al. (2012): Health-Related Quality-of-Life Outcomes: A Reflexology Trial With Patients With Advanced-Stage Breast Cancer +
Physical function level with SF-36: physical function subscale +
Wyatt et al. (2017): A Randomized Clinical Trial of Caregiver-Delivered Reflexology for Symptom Management During Breast Cancer Treatment +
Short forms of the PROMIS: Scale for physical functioning (study weeks 3, 5, 11) +
Wyatt et al. (2017): A Randomized Clinical Trial of Caregiver-Delivered Reflexology for Symptom Management During Breast Cancer Treatment +
Study week 3,5,11 +
Wyatt et al. (2017): A Randomized Clinical Trial of Caregiver-Delivered Reflexology for Symptom Management During Breast Cancer Treatment +
Summarized scale for symptom severity (study weeks 1-4, 5, 11) +
Wyatt et al. (2017): A Randomized Clinical Trial of Caregiver-Delivered Reflexology for Symptom Management During Breast Cancer Treatment +
Summarized scale for restrictions of daily life (study week 1-4, 5, 11) +
Wyatt et al. (2017): A Randomized Clinical Trial of Caregiver-Delivered Reflexology for Symptom Management During Breast Cancer Treatment +
PROMIS short forms: Satisfaction with regard to social participation (study weeks 3, 5, 11) +
Y
Yap et al. (2017): Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial +
Incidence of grade 2 or higher HFS in patients receiving pyridoxine +
Yap et al. (2017): Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial +
Time to HFS (CTCAE grade ≥ 2) +
Yap et al. (2017): Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial +
Quality of life (EuroQol EQ-5D-3L questionnaire): Baseline + at the beginning of the 2nd, 4th, 5th, 8th cycle + end of study +
Z
Zalat et al. (2020): Evaluation of the cardioprotective effects of l-carnitine and silymarin in cancer patients receiving anthracycline-containing chemotherapy +
Cardiotoxicity +
Zick et al. (2008): Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting +
? +
Zick et al. (2008): Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting +
Prevalence and severity of acute and delayed nausea and vomiting, more than 24 hours after chemotherapy +
Zick et al. (2008): Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting +
Prevalence and severity of acute nausea and vomiting (≤24h after Chemotherapy) +
Zick et al. (2008): Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting +
Blinding +
Ö